Boston Scientific (NYSE:BSX) is preparing to release its quarterly earnings on Wednesday, 2025-04-23. Here's a brief overview of what investors should keep in mind before the announcement.

Boston Scientific (BSX) closed the most recent trading day at $95.12, moving -0.14% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.13%. Meanwhile ...

Boston Scientific plans to break ground soon on a major expansion in Maple Grove, a project that’s up for $1.66 million in awards from DEED's Job Creation Fund.

The agreement to acquire involves Boston Scientific paying about $360 million for the 90% of SoniVie’s equity that Boston Scientific does not already own, plus up to an additional $180 million ...

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS ...

Boston Scientific has agreed to buy the rest of privately held medical-device company SoniVie for an initial $360 million in a deal that expands its portfolio of interventional cardiology therapies.

Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based ...

Boston Scientific, which currently has an equity stake of approximately 26% in Bolt Medical, in 2019 had created the concept for the company’s Bolt IVL system: a laser-based platform used to ...

Boston Scientific has had a major presence in Maple Grove for years. In 2005, the company opened a 120,000-square-foot research and development building at the Weaver Lake Road campus.

Boston Scientific is expanding its presence in cancer treatment as the Marlborough-based medical device manufacturer intends to acquire Intera Oncology, a Newton-based medical device company ...

Boston Scientific has become a big deal-maker under chief executive Mike Mahoney. – Topher Cox. For over a decade before the Guidant bidding war, Boston Scientific had been an aggressive deal-maker.